RenovaCare, Inc. (RCAR)

[NMBR1]

$RCAR THUNDER NEWS OUT
https://renovacareinc.com/new-skingun-sprays-skin-cells-onto-burns-and-wounds/?gclid=EAIaIQobChMIy5va5fCw3QIVTHsBCh3f2QtXEAEYASAAEgJKUvD_BwE

[bbartgen]

Thanks for the comment. I agree no news is not good.

[RayPruitt]

Im worried the patent dispute (although came out with a positive decision) may have halted development of the device until its completely sorted. The original spray on skin company is apparently weeks away from FDA decision. No news is not good news.

[badbass58]

Would not be shorting from here. PT Barnum say a sucker is born everyday. Not that this company is good.....but.....well.....lets see what happens with stock price from here.

[bbartgen]

Has there been an update on the fda approval process at all? I’ve emailed them several times with no response

[penywoo]

I just doubled down. If it goes to the one dollar. I will 10X down, not just double.

[bbartgen]

Anyone heard news on the fda approval process

[tdeck]

Ok I covered, not because of worry that it won't continue to fall but the $14K profit will be turned over 5-6 times by the time this POS hits under a buck. Too many shares shorted and too many will be covering slowly for the same reason as I am. Thanks for the dough. To all you hangers on since my first post wayyyyyyyyyyyy before I went short take this as your opportunity to exit, my last bit of free advice. Short covering is the only thing that is keeping it up and that is coming at a snails pace as it should no reason to cover in a hurry with this dog. Take care. Peace out.

[tdeck]

$1 a year right Harmel you keep telling yourself that lie, your the only one believing it, skull and crossbones and a new suicide hotline number for shareholders won't add anything to the volume or price, sorry reality bites all on the ass sooner or later. Peace out.

[tdeck]

Not to long now volume slowing to anemic levels should be able to cover in the pennies soon, very soon. Ta ta.

[tdeck]

You keep fighting that day trade pump fight my 2K shorted at 12.40 are just as safe as they were the first day I took the position and the next when I posted it here. Day traders delaying the inevitable, when I cover at a penny I will invite all you pumpers out for a drink, my treat. Peace out.

[Vilone]

Happening now

[tdeck]

I see they informed market they will release earnings on March 28, that's rich. They are gonna pump it to sell those shares right up until the very end LOL. See you at .0001.

I don't even usually short stocks but this was to easy, don't worry the money will be put to good use. Sorry sad but true. Peace out.

[Fire Misleading]

Let's do it.

[tdeck]

Daytraders just delaying the inevitable, my 2K shares short @12.40 previously posted about here shall not be covered till this thing goes under a $1 then fuck it, I will just bail not enough there to wait on and I would rather put the money to use elsewhere.

I am not even a shorter having short only 3 other stocks in 28 years of investing, but, damn, Ray Charles could have seen this was a scam.

But, as I said before this thing is headed to a .0001 ask where all scams go to die IMHO.

Peace out.

[XposeThem]

** MONSTER bounce imminent *** $6-$7!

[ammobox]

Good post tdeck, I'm not in RCAR Someone told me about it a few days ago. I took a look at it but seen how high is has ran in the last few weeks kind of figured there was some front loading going on and selling into the run, Their's no way I'd touch this. So I'm good.

Thanks for the post.

I do hope the person that told me about it made a few bucks on the run up.
Here's a possible winner RCAR. Bought 1000 shares at $6, its over $10 now

[tdeck]

If you read the PR closely you would notice that it was just a reissue of old stale lies and nonsense. I am very sorry for you all, but, I warned as did many others a long time ago that this was a boiler room type scam.

All that CNN, Bloomsberg, Newsweek and other magazines were articles etc paid for by the promoters. It was all smoke and mirrors, the cell gun is rubbish and if it weren't it would still have been a 3-5 year process and 10's of millions of dollars away from reality for use in any market let alone one as stringent as Americas, that's why most companies stock in this sector are very low until they get those patents FDA approvals etc..

I am not a mean person and hope none think I am. I am not relishing in your misfortune by any means. If you look most all that posted on this page posted once here and never again or only a few posts here, no doubt promoters of the scam.

If you have this type of technology and it is worth billions you are not pink and you do not get the Caveat Emptor (skull and crossbones) you are fully up to date with everything, have a team of lawyers and scientists, not one man answering the phone as your only employee and a drop off mailbox as a headquarters. It was all there but no one wanted to look at it which they (promoters) hope for they pull at peoples heart strings or greed whichever does the trick for that particular investor.

Take care I hope you do not lose to much of your investment, be more careful in the future, a simple google check of the people involved, directors, officers of the company and the history of this company with fraud, fines and convictions and the bogus patent case nonsnse may have opened your eyes. Dig deep when doing due diligence do not rely on some random posters saying rah rah its gonna change the world the rest are just lying to you.

Take care and good luck in your future investing, 99% of the companies are not like this one, just find a good one that is a safe investment and put your money there as well as in others, never put your eggs in just one basket.

Peace out.

[bar1080]

Skull & Crossbones



https://www.otcmarkets.com/stock/RCAR/overview

[bar1080]

"RenovaCare...Company’s shares will be traded on the OTC Markets Group Pink sheets platform. Currently, the stock trades with a caveat emptor designator imposed by the OTC Markets at their sole discretion citing public interest concerns, the specifics of which have not been provided to the Company, notwithstanding an earlier response to OTC Markets"

[ammobox]

RenovaCare Issues Important Shareholder Update Following Patent Win and FDA News

February 26, 2018 10:54 AM Eastern Standard Time
https://www.businesswire.com/news/home/20180226006027/en/

[bogblog]

I don't care about the fundamentals. Give me a hammer candle and I'll buy the shit out of it. Let's go bulls!

[SallyW]

I assumed Tdeck was just another annoying scam artist, but the facts that he has posted are true. Not sure if his intentions are altruistic or if he just wants to make sure his shorting of the stock is profitable.
The natural reaction when someone tells you that your stock choices are a bad is to push back at the poster and dismiss it as hype. Whenever I have done that in the past without checking the facts I have paid a huge price. We as investors are much more likely to be too optimistic, not many pessimistic stock investors. I have owned shares in RCAR for a couple of years now and I have been hearing negative things ever since I bought this stock. I paid $2.35 for the shares two years ago so at the current price I am up about 280%.
The negative things described in his posts can be attributed to most of the companies that I have invested in over the years. It seems to me that the RCAR management are more incompetent than criminal.
Maybe this time they will have a profit-making company. My rationale for holding this stock is that the science is good regardless of the current management.
If they are too incompetent to make this company work, once approvals are in place they should not have a problem selling this company especially with their patent in place.
Having said all that, I have just sold half of my shares. Like Tdeck I agree that the price was too high at current prices especially as the price increased as a result of dubious news from the company.
I will wait a while and will get back more shares when the fog lifts.
I agree with Tdeck this this management cannot be trusted, but the same is true of a lot of companies on the OTC.
Keep your eyes open and be prepared to jump ship when the boat starts rocking.
Goog luck to all

[tdeck]

WHAT IS RENOVACARE?

RenovaCare, Inc. is a biotechnology company focused on developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs.

On January 7, 2014, RCAR filed a Certificate of Amendment to Articles of Incorporation changing their name from “Janus Resources, Inc.” (natural resources exploration company) to “RenovaCare, Inc.” so as to more fully reflect their operations. The Financial Industry Regulatory Authority (“ FINRA ”) declared the name change effective as of January 9, 2014. In conjunction with the name change, RCAR changed their stock symbol on the OTCQB from “JANI” to “RCAR”.

So as you can see, from the get go, let’s understand we are talking about a company with less that 3 years of operation in the space. Lets go in deeper into the business opportunity presented in RCAR.

A number of organs have the intrinsic ability to regenerate, a distinctive feature that varies among organisms. Organ regeneration is a process not fully yet understood. However, when its underlying mechanisms are unraveled, it holds tremendous therapeutic potential for humans.

It is important to understand that RCAR can be considered a part of “transplantation business”. The global transplantation market size was estimated at USD 23.5 billion in 2016. The chart below shows the growing demand for these services.

There will be a major financial huge windfall of investment for any company that is coming close to finding the answer to proper organ regeneration. But there in lies the problem, Renovacare isnt make any progress yet it’s stock price has risen over 700% so far as of December 2016. From a humble valuation of $52 million dollars to over $568 million today yet never generating a single dollar in revenue.

Remember, this increase comes regardless of the fact that there have been no material progress made toward their stated goals. But this hasn’t stopped the company from attempting to look like they are making progress by attaching the company’s plans to academic papers that have nothing to do with Renovacare.

Here’s an excerpt from a recent news release located here.

RenovaCare, Inc., (OTCQB: RCAR), today highlighted an analysis of treatment results from 44 patients treated for severe second-degree wide-area burn injuries, as published in Burns, the peer-reviewed Journal of the International Society for Burn Injuries. The treatment method, which involved isolating and spraying the patient’s own skin stem cells on to burn wounds, is the technology underlying the RenovaCare patented SkinGun™* and CellMist™ System*.

This is very misleading use of language that could lead to an unattentive investor pouring thousands of dollars into a company they think has more potential than really is there.


Numbers for 2017 from online resources.

Cash: $1,149,604
Total Assets: $1,314,919
Total Liabilities: $1,110,368
Revenue: $0
Research and Development: $309,503
Total Operating Expenses: $1,898,222
Net Loss: $(2,693,646)
Stockholder Deficit :$(13,745,230)

This company doesn’t even have enough to cash on hand to meet current expenses. It has yet to produce a single dollar in revenue yet it’s stock price continues to go higher.

It is a beneficiary of the manipulation of a low and locked float that will eventually be broken and a deluge of selling will occur.

Here are most interesting insights from financial statements.

We currently have one full time employee, Mr. Andrew Danielson, Director of Operations, and three part-time contractors: Mr. Thomas Bold, President and Chief Executive Officer and Interim Chief Financial Officer; Ms. Patsy Trisler, Vice-President Clinical & Regulatory Affairs; and Dr. Roger Esteban-Vives, Director of Cell Sciences.

Can any company honestly be profitable with only 1 full time employee??

ITEM 1A. RISK FACTORS

Smaller reporting companies are not required to provide the information required by this item.

Company is stating that they will use OTC protections to not disclose materially important information that could prevent you from trading the company stock.

We currently finance our activities through the sale of our equity securities and issuance of debt. There is no assurance that funding will be accessible to us at the times and in the amounts required to fund our ongoing operations.

LOCATION

We do not own any properties. Our corporate offices are located at 430 Park Avenue, Suite 702, New York, NY 10022

Why would a company this poor rent an office in the most expensive commercial real estate center in America? Or maybe they arent renting an office but.. A MAILBOX!!

MANAGEMENT

The individual who holds the top position in the company does not appear to be an American citizen and does not appear have any experience in the field outside of other shell companies that have never shown any profitability. As mentioned earlier, he’s not even a full time employee so what does it matter.

[tdeck]

The Overvaluation Of RenovaCare Should Make Investors' Head Spin!
Feb.22.18 | About: RenovaCare, Inc. (RCAR)

Anna Vaysfeld
Short only, contrarian, research analyst, mid-cap
(18 followers)

Summary

If history is any lesson RCAR is a failure that shouldn't be expected to change..

Controlled by same majority shareholder for two decades. He was once fined by the SEC for illegal promotions.

Outrageous market capitalization as compared to its financial position.

RenovaCare, Inc. (OTC:OTCQB:RCAR), formerly Far West Gold, Inc., was incorporated in 1983. The earliest public filings that are available date back to 1999. Those financials reveal numerous and continuous unprofitable ventures spanning over two decades without generating any profitability for its shareholders'. Meanwhile the only aspect that is constant is the majority shareholder and a former executive Harmel S. Rayat.
A Lesson in RCAR's History

In 1999 RCAR was an American Alliance Corporation established in 1998 with plans to enter internet brokerage services business but did not, instead it acquired Whatsonline.com for $50,000 and entered an Internet streaming business.

Meanwhile, Hamel S. Rayat was its Chairman and a holder of 34.7 percent of the company and until 1998 was its President and Chief Executive.

At that early point in the company’s history this is how it described itself:

“The Company is a development stage company, as defined in Financial Accounting Standards Board No. 7. The Company is devoting substantially all of its present efforts in securing and establishing its business, and although its planned operations have commenced there have been no significant revenues derived therefrom”

So zero revenue, needs cash.

Next venture.

By year 2000, Whatsonline.com to which RCAR changed its name in 1999 was in the same condition as before, mainly,

“The Company did not generate revenues for the year ended December 31, 1999” and,

“Due to the "startup" nature of the Company's businesses, the Company expects to incur losses as it expands. The Company expects to raise additional funds through private or public equity investment in order to expand the range and scope of its business operations. The Company will seek access to private or public equity but there is no assurance that such additional funds will be available for the Company to finance its operations on acceptable terms, if at all”

Same year the board approved changing RCAR’s name from Whatsonline.com to Entheos Technologies, Inc. and sell its online assets.

At the time Entheos Technologies, Inc. was in business as an Application Service Provider (ASP) that developed real time, high volume outsourced email services through its wholly owned subsidiary Email Solutions, Inc.

According to annual report dated 3/30/2001 the new venture had only one revenue generating client, EquityAlert.com.

“Dependence on One Customer: In 2000, 100% of our total ASP revenues were generated from services provided to EquityAlert.com. The Company and EquityAlert.com have a common Director and majority shareholder. Our business, results of operations and financial condition could be materially adversely affected by the loss of this one customer, and such a loss could be concentrated in a single quarter. Further, if we do not continue to attract other customers, our business, results of operations and financial condition could be materially adversely affected.”

SEC commission in 2003 have issued a cease-and-desist proceedings against Entheos only client: EquityAlert.com and its Director and Chairman Harmel S. Rayat. EquityAlert.com, Inc., Innotech Corporation, Bhupinder S. Mann, Harmel S. Rayat, T&G

That was not the first time EquityAlert.com and Harmel S. Rayat were on SEC list, in 2000 the entity and Mr. Rayat were fined $20,000 for not disclosing payments for distribution of paid promotional matterial.

Entheos Technology operated for about ten years, (company states that it was operating from 2002 to 2008 but financials filed from 2000 to 2010) and keeping up with its predecessors did not generated any significant revenues or profits.

“ From 2002 until September 2008, through our wholly-owned subsidiary Email Solutions, Inc., we served as an Application Service Provider (“ASP”) providing outsourced email and search engine optimization services. Due to the limited success of our ASP business, management decided that it was in the best interest of our stockholders to abandon the Application Service Provider business and focus on identifying undervalued oil and gas opportunities for acquisition, development and exploration. The assets and liabilities, the results of operations and cash flows related to the ASP business were not classified as discontinued operations as the amounts were not significant. Email Solutions, Inc. was dissolved during 2008. “

Again, changing nature of its business and name, RCAR ventured into oil and natural gas business.

And again, Mr. Rayat was in control of it through a private corporation 1420525 Alberta Ltd., based in Vancouver, BC.

Still in control but no longer as an executive, he resigned in 2008, but as a majority shareholder of Entheos owning fifty-two percent.

From 2011 to 2014, RCAR was Janus Resources, Inc., an oil and gas developer with zero revenue and no profit, depending on capital raises to stay afloat. By the time Janus started to get out of exploring oil and gas business, their assets were worthless, and the company gave it away receiving only $3000 for it.

“ We entered into an Assignment Agreement with Leexus Oil LLC, the wells operator, whereby we assigned our right, title and interest in the oil, gas and mineral leases and the oil and gas wells. Payment for the assignment was the assumption of all outstanding liabilities and assumption of all future payments for any and all work performed on the wells. On February 19, 2013, we completed the sale of our working interest in the Cooke #6 well. We entered into an Assignment Agreement with Millennium Petro-Physics, the well operator, whereby we assigned our right, title and interest in the oil, gas and mineral leases and the oil and gas wells. Payment for the assignment was $3,000 cash.”

From here on the company became what we now know of as RCAR after its acquisition of TheCellMist System for $400,000.

Here is what the company had to say about its liquidity right before it went from Janus Resource to the current RenoveCare, Inc.;

“We currently finance our activities primarily by the private placement of our equity securities. There is no assurance that equity funding will be accessible to us at the times and in the amounts required to fund our ongoing operations. There are many conditions beyond our control which have a direct bearing on the level of investor interest in the purchase of our securities. We do not have any agreements or understandings with any person as to additional financing.”

Somewhere in between 2010 and 2012, Kalen Capital Corporation emerged as a new majority owner of Janus Resources, Inc. whose owner was Mr. Harmel Rayat, a holder of 63.9 percent.

And here is what today’s RCAR has to say about its business prospects, while Mr. Harmel Rayat and Kalen Capital holds 66.06 percent of its shares.

“The Company's ability to fund the development of its cellular therapies will depend on the amount and timing of cash receipts from future financing activities”

“However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to raise additional capital to accomplish its business plan. The Company expects to seek to obtain additional funding through the sale of its securities.”

In my opinion the valuation of RCAR is zero. The valuation is based on current asset values, as due to the lack of profitability in the last two decades it is impossible to value it in any other way.

RCAR generate no revenue thus revenue per share is zero. Working capital per share, a measure of liquidity, is also zero. With book value per share as a zero as well.

[bntoton]

There biotech is the real deal. I’m holding for another 10 years or more. Most likely will receive funding from the DOD once they initiate FDA enrollment, which is imminent since they won there patent.

[bogblog]

RaceCAR what a nice candle it put in today! Let's keep kicking ass longs = - D

Beautiful chart pattern for a squeeze on Monday.

[XposeThem]

Just playin bro.. nice bounce here though.. GL

[tdeck]

See you Monday, you will never in your wildest dreams get near me having to cover, but well done trading today. Still money for you to make no doubt, you have at least a week of playing with this thing as it does the inevitable, but, I am gonna sleep like a baby, this was my unicorn short and I am right as rain with this one. Have a great weekend guys, Peace out.

[XposeThem]

Tdek.. you need some pepto bismol
There big guy ?

[tdeck]

The Overvaluation Of RenovaCare Should Make Investors' Head Spin!
Feb.22.18 | About: RenovaCare, Inc. (RCAR)

Anna Vaysfeld
Short only, contrarian, research analyst, mid-cap
(18 followers)

Summary

If history is any lesson RCAR is a failure that shouldn't be expected to change..

Controlled by same majority shareholder for two decades. He was once fined by the SEC for illegal promotions.

Outrageous market capitalization as compared to its financial position.

RenovaCare, Inc. (OTC:OTCQB:RCAR), formerly Far West Gold, Inc., was incorporated in 1983. The earliest public filings that are available date back to 1999. Those financials reveal numerous and continuous unprofitable ventures spanning over two decades without generating any profitability for its shareholders'. Meanwhile the only aspect that is constant is the majority shareholder and a former executive Harmel S. Rayat.
A Lesson in RCAR's History

In 1999 RCAR was an American Alliance Corporation established in 1998 with plans to enter internet brokerage services business but did not, instead it acquired Whatsonline.com for $50,000 and entered an Internet streaming business.

Meanwhile, Hamel S. Rayat was its Chairman and a holder of 34.7 percent of the company and until 1998 was its President and Chief Executive.

At that early point in the company’s history this is how it described itself:

“The Company is a development stage company, as defined in Financial Accounting Standards Board No. 7. The Company is devoting substantially all of its present efforts in securing and establishing its business, and although its planned operations have commenced there have been no significant revenues derived therefrom”

So zero revenue, needs cash.

Next venture.

By year 2000, Whatsonline.com to which RCAR changed its name in 1999 was in the same condition as before, mainly,

“The Company did not generate revenues for the year ended December 31, 1999” and,

“Due to the "startup" nature of the Company's businesses, the Company expects to incur losses as it expands. The Company expects to raise additional funds through private or public equity investment in order to expand the range and scope of its business operations. The Company will seek access to private or public equity but there is no assurance that such additional funds will be available for the Company to finance its operations on acceptable terms, if at all”

Same year the board approved changing RCAR’s name from Whatsonline.com to Entheos Technologies, Inc. and sell its online assets.

At the time Entheos Technologies, Inc. was in business as an Application Service Provider (ASP) that developed real time, high volume outsourced email services through its wholly owned subsidiary Email Solutions, Inc.

According to annual report dated 3/30/2001 the new venture had only one revenue generating client, EquityAlert.com.

“Dependence on One Customer: In 2000, 100% of our total ASP revenues were generated from services provided to EquityAlert.com. The Company and EquityAlert.com have a common Director and majority shareholder. Our business, results of operations and financial condition could be materially adversely affected by the loss of this one customer, and such a loss could be concentrated in a single quarter. Further, if we do not continue to attract other customers, our business, results of operations and financial condition could be materially adversely affected.”

SEC commission in 2003 have issued a cease-and-desist proceedings against Entheos only client: EquityAlert.com and its Director and Chairman Harmel S. Rayat. EquityAlert.com, Inc., Innotech Corporation, Bhupinder S. Mann, Harmel S. Rayat, T&G

That was not the first time EquityAlert.com and Harmel S. Rayat were on SEC list, in 2000 the entity and Mr. Rayat were fined $20,000 for not disclosing payments for distribution of paid promotional matterial.

Entheos Technology operated for about ten years, (company states that it was operating from 2002 to 2008 but financials filed from 2000 to 2010) and keeping up with its predecessors did not generated any significant revenues or profits.

“ From 2002 until September 2008, through our wholly-owned subsidiary Email Solutions, Inc., we served as an Application Service Provider (“ASP”) providing outsourced email and search engine optimization services. Due to the limited success of our ASP business, management decided that it was in the best interest of our stockholders to abandon the Application Service Provider business and focus on identifying undervalued oil and gas opportunities for acquisition, development and exploration. The assets and liabilities, the results of operations and cash flows related to the ASP business were not classified as discontinued operations as the amounts were not significant. Email Solutions, Inc. was dissolved during 2008. “

Again, changing nature of its business and name, RCAR ventured into oil and natural gas business.

And again, Mr. Rayat was in control of it through a private corporation 1420525 Alberta Ltd., based in Vancouver, BC.

Still in control but no longer as an executive, he resigned in 2008, but as a majority shareholder of Entheos owning fifty-two percent.

From 2011 to 2014, RCAR was Janus Resources, Inc., an oil and gas developer with zero revenue and no profit, depending on capital raises to stay afloat. By the time Janus started to get out of exploring oil and gas business, their assets were worthless, and the company gave it away receiving only $3000 for it.

“ We entered into an Assignment Agreement with Leexus Oil LLC, the wells operator, whereby we assigned our right, title and interest in the oil, gas and mineral leases and the oil and gas wells. Payment for the assignment was the assumption of all outstanding liabilities and assumption of all future payments for any and all work performed on the wells. On February 19, 2013, we completed the sale of our working interest in the Cooke #6 well. We entered into an Assignment Agreement with Millennium Petro-Physics, the well operator, whereby we assigned our right, title and interest in the oil, gas and mineral leases and the oil and gas wells. Payment for the assignment was $3,000 cash.”

From here on the company became what we now know of as RCAR after its acquisition of TheCellMist System for $400,000.

Here is what the company had to say about its liquidity right before it went from Janus Resource to the current RenoveCare, Inc.;

“We currently finance our activities primarily by the private placement of our equity securities. There is no assurance that equity funding will be accessible to us at the times and in the amounts required to fund our ongoing operations. There are many conditions beyond our control which have a direct bearing on the level of investor interest in the purchase of our securities. We do not have any agreements or understandings with any person as to additional financing.”

Somewhere in between 2010 and 2012, Kalen Capital Corporation emerged as a new majority owner of Janus Resources, Inc. whose owner was Mr. Harmel Rayat, a holder of 63.9 percent.

And here is what today’s RCAR has to say about its business prospects, while Mr. Harmel Rayat and Kalen Capital holds 66.06 percent of its shares.

“The Company's ability to fund the development of its cellular therapies will depend on the amount and timing of cash receipts from future financing activities”

“However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to raise additional capital to accomplish its business plan. The Company expects to seek to obtain additional funding through the sale of its securities.”

In my opinion the valuation of RCAR is zero. The valuation is based on current asset values, as due to the lack of profitability in the last two decades it is impossible to value it in any other way.

RCAR generate no revenue thus revenue per share is zero. Working capital per share, a measure of liquidity, is also zero. With book value per share as a zero as well.

[tdeck]

Well done I told you I knew you would make a good play and make money. I just knew I was safe, to much money to get to where it would even make me think twice, well done, you may get out in the 9's nice trade.

[BullishSwag]

Boy my 7.35’s sure are looking good right about now :)

[tdeck]

I got lucky, I made a hit on a penny and knew about this POS already and saw the move up Wednesday and even though I rarely short stocks I knew everything about this and decided to short it with the profits. I was gonna short it at $11 and darn if the thing didn't climb past $12. I was worried a little but it stopped at $12.80 or so I can't remember and pop goes the weasel.

And the best thing about this was it had no product that even if it was viable was 3-5 years out if they tried to get it approved and where was the money to come from they had none.

Twitter was blowing up how it was gonna crash what a shame and even normal momentum players like myself were saying they were not even going to play it anymore. It was like taking candy from a baby. Nothing there it had its moment in the sun and I got lucky, plain and simple. And to keep trying to hype it higher is ludicrous, I mean really, game over. Peace out.

[dubey]

I am a young guy, with not enough skin in the game, but I would have loved to short this dead beat stock. Have a wagayu tomahawk for me tonight!

[tdeck]

Sometimes when someone is shot and you tell them they are dying they just don't want to believe it, they really actually believe all that tripe. PT Barnum said a sucker born every day, come on momentum try and knock me off my perch up here at $12.40

I am going out for steak tonight. tee _ucking hee

[dubey]

Keep fighting the good fight tdeck!! That patent victory press release was hilarious, the patent ruling was finalized months ago. RCAR pumping the stock up with old news so they can inside trade millions.

[tdeck]

That was proven as a fake, sorry Charlie. Never was a court case the supposed plaintiffs released a PR in Australia saying they knew nothing about it.

[BullishSwag]

RenovaCare Secures Patent Victory and Continues to Bolster IP Portfolio

2/21/18, 6:30 AM
PITTSBURGH & BERLIN--(BUSINESS WIRE)-- RenovaCare, Inc., (RCAR), developer of the SkinGun™ and CellMist™ System for spraying a patient’s own skin stem cells onto burns and wounds for rapid self-healing, announced it has decisively won against patent challenger, Avita Medical, in a proceeding at the United States Patent Office (USPTO).

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005733/en/

Burned State Trooper Leaves Hospital 4 Days After RenovaCare Stem Cell Spray. Photo source: National ...
Burned State Trooper Leaves Hospital 4 Days After RenovaCare Stem Cell Spray. Photo source: National Geographic Explorer.

Noting that Avita’s arguments were based on old claims and technologies which had already been considered and rejected, the USPTO dismissed the challenge immediately and denied a trial sought by Avita.

“I’m proud of the cutting-edge technologies developed by our team for the millions that suffer from burns and wounds and deserve access to the very latest in medical innovation,” stated Mr. Thomas Bold, President and CEO of RenovaCare.

“Just as we’ve done with this challenge, we’ll aggressively protect our intellectual property while continuing to expand our patent portfolio and enhance shareholder value.”

To-date more than 70 human patients with severe second-degree burns have been treated with the technology behind the RenovaCare SkinGun and its patents. Clinical results, case studies and data have been presented in numerous peer-reviewed publications.

Treated with a gentle spray of their own skin stem cells, many patients have left the hospital within a matter of days, healed with full mobility and scar-free.

In contrast, patients who undergo skin grafting, today’s default treatment, can remain hospitalized for weeks and months while enduring multiple painful surgeries and prolonged physical therapy. Skin graft patients can suffer with the painful psychological effects of disfigurement caused by permanent scarring and are often forced to cope with the ongoing use of pain medications and protracted joint mobility issues.

Another option, in-vitro cultured epithelial grafts, requires harvesting cells from a patient, which are then transported to a specialized external laboratory where they take weeks to form sheets of skin. These fragile sheets must then be shipped back to the hospital for surgical stitching onto a patient’s wounds, a process that is complicated, time-consuming and expensive.

The Company has developed its novel SkinGun for the ultra-gentle spray of a patient’s own skin stem cells on to burns and wounds for rapid healing. The potent, regenerative cells are isolated from a postage stamp sized donor site and suspended in a liquid, the CellMist Solution. The CellMist Solution is then sprayed on to wounds using the SkinGun. The entire procedure can be completed in as little as 90 minutes.

The SkinGun spray device and cell isolation methodology are subjects of patents awarded to RenovaCare in the United States and Europe. The company has also filed additional patent applications and continues expanding its intellectual property portfolio.

Click here to watch State Trooper’s amazing stem cell recovery.

Click here to view before-and-after photos in peer-reviewed publications.

*RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the company’s planned or filed submissions to the U.S. Food and Drug Administration, if any, will be accepted or cleared by the FDA.

About RenovaCare

RenovaCare, Inc. is developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs, and novel medical grade liquid sprayer devices. RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.

For additional information, please call Drew Danielson at: 888-398-0202 or visit: https://renovacareinc.com

To receive future press releases via email, please visit: https://renovacareinc.com/investors/register/

Follow us on Twitter https://twitter.com/RenovaCareInc or follow us on Facebook https://www.facebook.com/renovacarercar

For answers to frequently asked questions, please visit our FAQ’s page: https://renovacareinc.com/investors/faqs/

Social Media Disclaimer

Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders, and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the company’s website and the social media channels listed below:

Facebook
Twitter
*This list may be updated from time to time.

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company’s technologies, technical problems with the Company’s research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



View source version on businesswire.com: http://www.businesswire.com/news/home/20180221005733/

[tdeck]

Houston we have a problem. Meanwhile Scotty is in the engine room telling Captain Kirk "I'm giving you everything I can get out of her, but the bidders are not following the ask slappers" Oh dear. Whatever shall we do.

Telling you this was a once in a year short everything was perfect for it, your pushing a huge rock up that hill. $10 will not even make me light a cigarette let alone help push this pig anywhere. $13.40 will make me take notice, and that is NEVER gonna happen.

You think I am alone up here, sheeeeeeeet I bet not. Good luck getting through all those retail sellers with their fingers on the trigger wanting to just get even after that morning scare. Chit be frightening. tee heee heee heee heee

[BullishSwag]

He will be the one that runs it over 10$ when he realizes he fooked up

[tdeck]

This pig has to hit $13.40 before I even start to get nervous.

[tdeck]

Not with hyped up stuff like this, pushed to hard to high to fast with absolutely nothing to hold it there.

And now they have who knows how many boiler room retail investors biting their collective fingernails hoping it pops high enough for them to bail, with a little bit of skin left. Strong headwinds ahead bro, but gl to you I am sure you will make a decent trade and make some dough, but, I am as safe as a baby in its mothers arms on this one.

They have nothing and no future except .0001 that my friend is just to easy, shorts like this only come down the pike once in a blue moon and I got lucky enough to catch this one just right with some excess cash I got lucky and made on a penny this week so this play is with the $$$ from 50K free shares and I am loving life, Every dog gets a warm part of the sidewalk every once in a while. See you in the funny papers.

[XposeThem]

Tdeck cover before a huge loss- don't say I didn't warn you

[BullishSwag]

Greed will kill u pal

[XposeThem]

HUGE short squeeze incoming- mark my words

[tdeck]

Shorted yesterday @12.40 not gonna cover until it hits the pennies. Thanks anyway, this one was to easy.

[BullishSwag]

Agree

[BullishSwag]

Trend line just broke better cover

[XposeThem]

<<<MONSTER BOUNCE INEVITABLE>>>

$10-12!!!